PAQ Therapeutics reported on 20 November 2026 preliminary Phase 1 results for its selective KRAS G12D degrader PT0253 in advanced solid tumors, showing no dose-limiting toxicities across 10 to 750 mg and early responses in monotherapy and first-line pancreatic cancer.
PAQ Therapeutics, First Clinical Data for PT0253 KRAS G12D Degrader at ENA 20264 min read Data included
UNICEF reported more than 74 million doses procured and delivered by 22 October. That is a delivery count, distinct from completed vaccination courses or a 2030 target for children.
Unverified historical source reference (former attribution: Gavi Vaccine Alliance Operational Monitoring)3 min read Data included
National synchrotron facility unveils sub-angstrom macromolecular crystallography beamline enabling atomic-resolution analysis of membrane protein pathogens.
Canadian Light Source Scientific Bulletin3 min read Data included
Interior Health and BC Cancer awarded the primary construction contract on 3 November 2026 for the $359 million, five-storey Kamloops Cancer Centre at Royal Inland Hospital, housing three linear accelerator radiation vaults and a 30-bay chemotherapy clinic.